Clinical Data REGENXBIO slumps after serious side effects mar Duchenne gene therapy results BioSpaceShares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call Thursday.Gene Therapy PlatformRead full story pharminent May 14, 2026 (Last updated: May 21, 2026) BioSpace Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company’s first quarter earnings call Thursday. Gene Therapy Platform Read full story Post navigation Previous: Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimismNext: Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drug Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
